Last edition
News about
India Reaffirms Commitment to Traditional Medicine at 9th Siddha Day Celebrations in Chennai
The 9th Siddha Day celebrations highlighted India’s traditional systems of medicine as living, holistic and preventive healthcare practices, with a strong focus on Siddha’s relevance to modern and global health needs.
TempraMed Expands South Korea Footprint with Fresh Commercial Order, Extends Distribution Pact
TempraMed Technologies Ltd., a medical-technology company focused on improving the storage and handling of temperature-sensitive medications, has secured a new commercial order and extended its distribution partnership in South Korea, strengthening its presence in the Asian healthcare market.
ScinoPharm Wins FDA Approval for Glatiramer Acetate Injection
ScinoPharm Taiwan has received US FDA approval for its Glatiramer Acetate Injection for the treatment of multiple sclerosis, marking a significant milestone as the first and only Taiwanese pharmaceutical company to secure FDA approval for this complex generic, and reinforcing Taiwan’s growing role in the global pharmaceutical supply chain.
FDA Clears BrainSpace's Intellidrop for Automated, Closed-Loop Brain Fluid Management
BrainSpace, a medical technology company developing automated solutions for neurological injury, disease and degeneration, has received US Food and Drug Administration (FDA) 510(k) clearance for Intellidrop, its automated brain fluid management system.
Orum Therapeutics Appoints Dr Chad May as Chief Scientific Officer
Orum Therapeutics has appointed Dr Chad May, PhD, as Chief Scientific Officer (CSO), who brings over two decades of oncology and immunology research experience to advance the company’s degrader-antibody conjugate platform and pipeline of next-generation therapies.
MHRA Approves New mRNA COVID-19 Booster
The new approved vaccine, Zapomeran (Kostaive) is cleared for adults aged 18 years and above.
HUTCHMED Begins Phase III Trial of Surufatinib-Camrelizumab Combo in Pancreatic Cancer
HUTCHMED has initiated the phase-III stage of its phase-II/III clinical trial in China evaluating a combination regimen of surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma, with the first patient dosed on 30 December, 2025.
Novo Nordisk Secures Key China Patent Win for Semaglutide
The Supreme People’s Court of China has delivered a favourable ruling on the intellectual property rights related to the semaglutide compound patent, upholding an earlier decision by the Beijing Intellectual Property Court that confirmed the patent’s validity.
BioAtla Advances Phase 3 Oz-V Programme with Manufacturing-Ready SPV Structure
BioAtla, Inc., a global clinical-stage biotechnology company developing Conditionally Active Biologic (CAB) antibody therapies for solid tumours, has entered into a special purpose vehicle (SPV) transaction with GATC Health Corp. to advance its lead asset, ozuriftamab vedotin (Oz-V), into a phase 3 clinical trial for second-line and later OPSCC.
Samsung Bioepis Launches BYOOVIZ Biosimilar in Europe
Samsung Bioepis has completed the transfer of BYOOVIZ commercial rights from Biogen, making it the company’s fourth biosimilar directly marketed in Europe, with a pre-filled syringe launch planned for Q2 2026.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy